These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 780113)

  • 1. Phase I clinical trial of a 3-day divided dose schedule of ifosfamide (NSC 109724).
    Nelson RL; Creaven PJ; Cohen MH; Fossieck BE
    Eur J Cancer (1965); 1976 Mar; 12(3):195-8. PubMed ID: 780113
    [No Abstract]   [Full Text] [Related]  

  • 2. Reduction of ifosfamide toxicity using dose fractionation.
    Rodriguez V; Bodey GP; Freireich EJ; McCredie KB; McKelvey EM; Tashima CK
    Cancer Res; 1976 Aug; 36(8):2945-8. PubMed ID: 1277203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I clinical trial of isophosphamide (NSC-109724).
    Cohen MH; Creaven PJ; Tejada F; Hansen HH; Muggia F; Mittelman A; Selawry OS
    Cancer Chemother Rep; 1975; 59(4):751-5. PubMed ID: 1100226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxicity of single- vs. fractionated-dose ifosfamide in non-small cell lung cancer: a multi-center study.
    Morgan LR; Harrison EF; Hawke JE; Hunter HL; Costanzi JJ; Plotkin D; Tucker WG; Worrall PM
    Semin Oncol; 1982 Dec; 9(4 Suppl 1):66-70. PubMed ID: 7163813
    [No Abstract]   [Full Text] [Related]  

  • 5. Studies on the clinical pharmacology and toxicology of isophosphamide (NSC-109724).
    Creaven PJ; Allen LM; Cohen MH; Nelson RL
    Cancer Treat Rep; 1976 Apr; 60(4):445-9. PubMed ID: 1277220
    [No Abstract]   [Full Text] [Related]  

  • 6. Single-dose ifosfamide: efficacy studies in non-small cell lung cancer.
    Harrison EF; Hawke JE; Hunter HL; Costanzi JJ; Morgan LR; Plotkin D; Tucker WG; Worrall PM
    Semin Oncol; 1982 Dec; 9(4 Suppl 1):56-60. PubMed ID: 6298944
    [No Abstract]   [Full Text] [Related]  

  • 7. [Ifosfamide in the treatment of small cell carcinoma of the lung].
    Mukouda K; Morikawa E; Hasegawa K; Noumi K; Ohmura T; Mishima Y; Kawamoto M; Inagaki A; Kamitsuna A; Yamakido M; Nishimoto Y; Koyama T; Katsuta S
    Gan To Kagaku Ryoho; 1983 May; 10(5):1293-8. PubMed ID: 6307164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical experience with the cytostatic drug ifosfamide].
    Ritter S; Schröder HJ
    Med Welt; 1977 Sep; 28(35):1395-1400. PubMed ID: 70737
    [No Abstract]   [Full Text] [Related]  

  • 9. [Clinical evaluation of Mitexan in the prevention of urinary tract complications during treatment with Holoxan].
    Czownicki Z; Utracka-Hutka B
    Nowotwory; 1981; 30(4):377-83. PubMed ID: 6792599
    [No Abstract]   [Full Text] [Related]  

  • 10. [Experience with fractionate massive-dose Ifosfamid therapy of generalized malignant tumors].
    Hoefer-Janker H; Scheef W; Günther U; Hüls W
    Med Welt; 1975 May; 26(20):972-9. PubMed ID: 1094226
    [No Abstract]   [Full Text] [Related]  

  • 11. Mesnum as a protector against kidney and bladder toxicity with high-dose ifosfamide treatment.
    Falkson G; Van Dyk JJ; Stapelberg R; Falkson HC
    Cancer Chemother Pharmacol; 1982; 9(2):81-4. PubMed ID: 6816479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use and safety of high-dose ifosfamide.
    Holoye PY; Anderson T; Duelge J; Hansen RM; Ritch PS
    Semin Oncol; 1982 Dec; 9(4 Suppl 1):78-86. PubMed ID: 6298946
    [No Abstract]   [Full Text] [Related]  

  • 13. Prophylaxis of ifosfamide toxicity with oral acetylcysteine.
    Holoye PY; Duelge J; Hansen RM; Ritch PS; Anderson T
    Semin Oncol; 1983 Mar; 10(1 Suppl 1):66-71. PubMed ID: 6836329
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of refractory malignant neoplasms with ifosfamide as single agent and in combination chemotherapy.
    Retsas S
    Cancer Treat Rev; 1983 Sep; 10 Suppl A():151-7. PubMed ID: 6627241
    [No Abstract]   [Full Text] [Related]  

  • 15. Evaluation of a cooperative clinical study of the cytostatic agent ifosfamide.
    Schnitker J; Brock N; Burkert H; Fichtner E
    Arzneimittelforschung; 1976; 26(10):1783-92. PubMed ID: 798586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ifosfamide--current aspects and perspectives.
    Hilgard P; Herdrich K; Brade W
    Cancer Treat Rev; 1983 Sep; 10 Suppl A():183-92. PubMed ID: 6414693
    [No Abstract]   [Full Text] [Related]  

  • 17. Ifosfamide continuous infusion without mesna. A phase I trial of a 14-day cycle.
    Lokich I; Anderson N; Bern M; Moore C
    Cancer; 1991 Feb; 67(4):883-5. PubMed ID: 1899352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ifosfamide in the treatment of extensive non-oat cell carcinoma of the lung.
    Costanzi JJ; Morgan LR; Hokanson J
    Semin Oncol; 1982 Dec; 9(4 Suppl 1):61-5. PubMed ID: 6298945
    [No Abstract]   [Full Text] [Related]  

  • 19. [Treatment of bronchogenic cancer and lung metastases of solid tumors with ifosfamid (author's transl)].
    Hoefer H; Scheef W; Titscher R; Kokron O
    Osterr Z Onkol; 1974; (1):3-7. PubMed ID: 4619650
    [No Abstract]   [Full Text] [Related]  

  • 20. N-acetylcysteine and ifosfamide in the treatment of unresectable pancreatic adenocarcinoma and refractory testicular cancer.
    Loehrer PJ; Williams SD; Einhorn LH
    Semin Oncol; 1983 Mar; 10(1 Suppl 1):72-5. PubMed ID: 6836331
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.